Evidence map›Paper›PMID 35202705›Full record

ArticleExperimental eye research2022

Alzheimer's disease amyloid-β pathology in the lens of the eye.

Juliet A Moncaster, Robert D Moir, Mark A Burton, Oliver Chadwick, Olga Minaeva, Victor E Alvarez, Maria Ericsson, John I Clark, Ann C McKee, Rudolph E Tanzi and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Experimental eye research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Ocular changes as potential biomarkers for early diagnosis of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Roles and regulation of δ-catenin in tumorigenesis and neuronal diseases.Frontiers in cell and developmental biology · 2025
    Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. A Wide Range of Eye Diseases.Deutsches Arzteblatt international · 2023
    Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Juliet A MoncasterMolecular Aging and Development Laboratory, Boston University School of Medicine, Boston, MA, 02118, USA; Boston University Alzheimer's Disease Research Center, Boston University School of Medicine, 72 East Concord Street, B-7800 Boston, MA, 02118, USA.
Robert D MoirGenetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.
Mark A BurtonMolecular Aging and Development Laboratory, Boston University School of Medicine, Boston, MA, 02118, USA.
Oliver ChadwickGenetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.
Olga MinaevaMolecular Aging and Development Laboratory, Boston University School of Medicine, Boston, MA, 02118, USA; Boston University Alzheimer's Disease Research Center, Boston University School of Medicine, 72 East Concord Street, B-7800 Boston, MA, 02118, USA.
Victor E AlvarezBoston University Alzheimer's Disease Research Center, Boston University School of Medicine, 72 East Concord Street, B-7800 Boston, MA, 02118, USA; Edith Nourse Rogers Memorial Veterans' Hospital, Bedford, MA, 01730, USA.
Maria EricssonElectron Microscopy Facility, Harvard Medical School, Boston, MA, 02115, USA.
John I ClarkDepartments of Biological Structure and Ophthalmology, University of Washington, Seattle, WA, 98195, USA.
Ann C McKeeBoston University Alzheimer's Disease Research Center, Boston University School of Medicine, 72 East Concord Street, B-7800 Boston, MA, 02118, USA; Edith Nourse Rogers Memorial Veterans' Hospital, Bedford, MA, 01730, USA.
Rudolph E TanziGenetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.
Lee E GoldsteinMolecular Aging and Development Laboratory, Boston University School of Medicine, Boston, MA, 02118, USA; Boston University Alzheimer's Disease Research Center, Boston University School of Medicine, 72 East Concord Street, B-7800 Boston, MA, 02118, USA. Electronic address: lgold@bu.edu.
Boston University · USHarvard University · USUniversity of Washington · US

Funding

RL5: Research Education CoreP30AG072978 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Ann C. McKee · 2021 to 2026
$25.6M
Tau Pathology in CTE vs. Alzheimer's Disease: Microvasculopathy and NeuroinflammationRF1AG057902 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MCKEE, ANN C. · 2017 to 2017
$4.1M
Precision Brain Health Monitoring for Alzheimer's Disease Risk Detection in the Framingham Study: Black & AA Recruitment SupplementRF1AG072654 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI AU, RHODA, GOLDSTEIN, LEE E. · 2021 to 2023
$2.4M
Lens β-Amyloid Biomarker for Early Detection of Preclinical Alzheimer's Disease in the Framingham StudyRF1AG072589 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GOLDSTEIN, LEE E. · 2021 to 2021
$1.7M
AD LENS PATHOLOGY: BIOCHEMISTRY &DIAGNOSTIC IMAGINGR01GM075986 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI GOLDSTEIN, LEE E. · 2005 to 2010
$1.5M
Precision Brain Health Monitoring for Alzheimer's Disease Risk Detection in the Framingham StudyR01AG072654 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Rhoda Au, LEE E. GOLDSTEIN · 2025 to 2026
$1.1M
NIA NIH HHS P30 AG072978NIA NIH HHS R01 AG072654NIA NIH HHS RF1 AG057902NIA NIH HHS RF1 AG072589NIA NIH HHS RF1 AG072654NIGMS NIH HHS R01 GM075986
6 · The paper itself

Abstract

Neuropathological hallmarks of Alzheimer's disease (AD) include pathogenic accumulation of amyloid-β (Aβ) peptides and age-dependent formation of amyloid plaques in the brain. AD-associated Aβ neuropathology begins decades before onset of cognitive symptoms and slowly progresses over the course of the disease. We previously reported discovery of Aβ deposition, β-amyloidopathy, and co-localizing supranuclear cataracts (SNC) in lenses from people with AD, but not other neurodegenerative disorders or normal aging. We confirmed AD-associated Aβ molecular pathology in the lens by immunohistopathology, amyloid histochemistry, immunoblot analysis, epitope mapping, immunogold electron microscopy, quantitative immunoassays, and tryptic digest mass spectrometry peptide sequencing. Ultrastructural analysis revealed that AD-associated Aβ deposits in AD lenses localize as electron-dense microaggregates in the cytoplasm of supranuclear (deep cortex) fiber cells. These Aβ microaggregates also contain αB-crystallin and scatter light, thus linking Aβ pathology and SNC phenotype expression in the lenses of people with AD. Subsequent research identified Aβ lens pathology as the molecular origin of the distinctive cataracts associated with Down syndrome (DS, trisomy 21), a chromosomal disorder invariantly associated with early-onset Aβ accumulation and Aβ amyloidopathy in the brain. Investigation of 1249 participants in the Framingham Eye Study found that AD-associated quantitative traits in brain and lens are co-heritable. Moreover, AD-associated lens traits preceded MRI brain traits and cognitive deficits by a decade or more and predicted future AD. A genome-wide association study of bivariate outcomes in the same subjects identified a new AD risk factor locus in the CTNND2 gene encoding δ-catenin, a protein that modulates Aβ production in brain and lens. Here we report identification of AD-related human Aβ (hAβ) lens pathology and age-dependent SNC phenotype expression in the Tg2576 transgenic mouse model of AD. Tg2576 mice express Swedish mutant human amyloid precursor protein (APP-Swe), accumulate hAβ peptides and amyloid pathology in the brain, and exhibit cognitive deficits that slowly progress with increasing age. We found that Tg2576 trangenic (Tg

Indexed as

Alzheimer DiseaseCataractNeurodegenerative DiseasesAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsBrainDisease Models, AnimalGenome-Wide Association StudyHumansMiceMice, TransgenicAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAlzheimer's diseaseAmyloid precursor proteinAmyloid-βAβBiomarkerCataractDown syndromeLensProtein aggregationQuasi-elastic light scatteringTransgenic mouse model

Identifiers

PMID35202705
PMCPMC9873124
OpenAlexW4212992853

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.